Johnson & Johnson's Janssen unit said that its prostate cancer drug Zytiga (abiraterone acetate) delayed the progression of cancer in chemotherapy-naive patients. The late-stage trial COU-AA-302 of Zytiga in 1,088 patients with castration-resistant prostate cancer has been unblinded due its effectiveness, ...

Johnson & Johnson (J&J) has halted a clinical study of its antibiotic Doribax after an interim analysis revealed a higher death rate for patients treated with the drug than those in a control treatment group . The carbapenem antibiotic Doribax was already approved for urinary and abdominal ...

The U.S firm Johnson & Johnson is seeking the approval of FDA to expand the use of  its new anticlotting pill, Xarelto.   Johnson & Johnson's pharma unit Janssen has submitted a supplemental new drug application (sNDA) to the FDA seeking approval for the use of Xarelto ...

Janssen Biotech Inc., an unit of Johnson & Johnson, has signed a collaboration agreement with Pharmacyclics to develop and commercialize the latter's oral drug candidate PCI-32765 for non-Hodgkins lymphoma, chronic lymphocytic leukemia and multiple myeloma. Janssen will pay an upfront fee of $150 million for the right ...

Johnson & Johnson ($JNJ) and AstraZeneca ($AZN) have slammed the brakes on ongoing clinical trials of their next-gen painkillers, the latest victims of serious side effects that have been linked to a drug class that once was believed to h...

Xarelto shows improved safety profile Xarelto, the once-daily anticoagulant developed by Johnson & Johnson and Bayer could  prevent strokes in patients with atrial fibrillation better than standard therapy warfarin as indicated in a late-stage clinical study enrolled 14,264 patients. The experimental ...

Arena announced that Johnson & Johnson will end its deal for Arena Pharmaceuticals' diabetes drug APD597 after seeing Phase I results. Johnson & Johnson has notified Arena that it is terminating the collaboration, effective December 28, 2010. Upon termination of ...

Abiraterone increase  survival in advanced prostate cancer patients  The pharma group Johnson & Johnson reported very impressive data from the Phase III trial of its targeted oral androgen biosynthesis inhibitor, abiraterone acetate in patients with metastatic advanced prostate cancer.   Presented at the 35th ...

FDA issues complete response letter for tapentadol NDA Johnson & Johnson Pharmaceutical Research & Development's new drug application (NDA) for Tapentadol extended release tablets has received a complete response letter from the US FDA, according to ...

Johnson & Johnson (NYSE: JNJ) unit Tibotec Pharmaceuticals has reported results from two pivotal Phase III trials comparing its investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) with efavirenz. ...